An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new report looked at FDA safety reports to see whether people without diabetes who are taking semaglutide (sold as Ozempic, Wegovy) or tirzepatide (Zepbound, Mounjaro when used for diabetes) for weight loss are showing more cases of ketoacidosis, a serious metabolic problem. The researchers compared how often ketoacidosis shows up in the US drug-safety database for semaglutide versus tirzepatide in people who do not have diabetes. They did not run a clinical trial — they skimmed an existing safety-reporting system for signals. Semaglutide is a drug that mimics a gut hormone that helps control appetite and blood sugar. People know it by brand names like Ozempic and Wegovy. It slows stomach emptying and tells the brain you’re fuller, which helps reduce weight. Tirzepatide is a newer drug that acts on two related gut-hormone pathways and tends to produce larger weight loss in trials. Both drugs are injected and used increasingly for obesity, including in people who do not have diabetes. What the researchers actually did was a “disproportionality analysis” of the FDA Adverse Event Reporting System (FAERS). That means they counted reports of ketoacidosis linked to each drug in that database and compared the numbers to see if one drug had a higher-than-expected share of reports. This kind of study looks for signals, not proof. The database contains voluntary reports that can be incomplete, duplicated, or biased by publicity. The paper suggests there was a difference in reported ketoacidosis cases between the two drugs in non-diabetic patients, but it cannot establish cause-and-effect or precise risk rates because the underlying number of people taking each drug and the reasons for reporting are unknown. Why this matters is straightforward: ketoacidosis is a potentially life-threatening condition where the body makes excess acids called ketones, most commonly seen in people with type 1 diabetes. If weight-loss drugs being used by people without diabetes are linked to more ketoacidosis reports, clinicians and patients should be aware and watch for symptoms like deep, rapid breathing, abdominal pain, vomiting, confusion, or unusual fatigue. People considering or already on these medications for obesity might want to discuss monitoring plans with their doctor, especially if they have other health issues or take medications that raise ketone risk. There are important caveats. This study used a voluntary safety-reporting database, which is prone to reporting bias and doesn’t prove the drugs cause ketoacidosis. The analysis can’t tell how common the problem really is, who is most at risk, or whether the imbalance could be due to more people using one drug or to media attention. Also, the report focused on non-diabetic users, but the FDA and clinicians already monitor for ketoacidosis mainly in people with diabetes. If you have concerns, don’t stop or start these medicines on your own — talk to your healthcare provider. Bottom line: the paper raises a safety signal worth watching, but it’s not definitive proof that one drug causes more ketoacidosis than the other.
Source: Cureus